Beta 2 antagonism in acute respiratory failure
1 Regional Intensive Care Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland
2 Centre for Infection and Immunity, Health Sciences Building, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland
3 McMaster University, Faculty of Health Sciences, 1200 Main Street West, Room 2C8, Hamilton, ON, Canada, L8N 3Z5
Critical Care 2010, 14:1012 doi:10.1186/cc9359
See related research by Noveanu et al., http://ccforum.com/content/14/6/R198Published: 20 December 2010
Post hoc analyses from the B-type natriuretic peptide for Acute Shortness of Breath Evaluation (BASEL)-II-ICU study suggest an association between beta-blocker usage at admission and improved mortality in patients treated in the intensive care unit for acute respiratory failure. Although this evidence is encouraging, there is a need for a phase 2 proof-of-concept randomized controlled trial of beta-blocker therapy in patients admitted with acute respiratory failure.